Chemed Corporation (CHE) Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

VITAS Healthcare:

Net revenue: $407.7 million, up 4.2% year-over-year.

Average revenue per patient day: $205.08, a 2.98% increase from the prior year.

Adjusted EBITDA (excluding Medicare Cap): $70.4 million, down 3.8% year-over-year; EBITDA margin: 17.0%.

Roto-Rooter:

Revenue: Increased 1.1% year-over-year.

Branch residential revenue: $150.9 million, up 3.4%; commercial revenue: $55 million, up 2.8%.

Adjusted EBITDA: $49.4 million, down 12.4% year-over-year; EBITDA margin: 22.7%.

2Strategic Updates and Business Highlights

VITAS successfully managed Florida Medicare Cap billing limitations, achieving a billing limit of $18.9 million, slightly better than the estimated $19 million.

Hospital admissions for VITAS reached 44.5%, indicating a strong focus on hospital-based admissions, which is crucial for long-term stability.

Roto-Rooter saw an increase in residential plumbing revenue by 8.2%, attributed to targeted marketing campaigns.

The new Pinellas County location for VITAS is set to open in early November, with expectations for growth in the Marion County program.

3Forward Guidance and Outlook

Management reiterated full-year guidance of $22 to $22.30 per share, excluding noncash expenses.

VITAS is expected to have a strong fourth quarter, traditionally its best, with anticipated margin improvements due to new Medicare rates.

Roto-Rooter is projected to benefit from seasonal weather conditions, which typically increase job volume in the colder months.

4Bad News, Challenges, or Points of Concern

Roto-Rooter’s revenue from independent contractors declined by 4.7%, indicating challenges in that segment.

Adjusted EBITDA margins for both segments fell below long-term expectations, with Roto-Rooter margins particularly under pressure due to increased marketing costs.

There are concerns regarding the sustainability of lead generation, with a noted shift from unpaid to paid leads, which could impact margins.

5Notable Q&A Insights

Management acknowledged that the slight underperformance in Q3 results compared to market expectations was due to seasonal trends and reaffirmed confidence in achieving guidance for Q4.

Discussions highlighted the importance of managing the mix of hospital admissions to improve profitability, with a focus on balancing short-stay and long-stay patients.

There were concerns about elevated Days Sales Outstanding (DSO), primarily attributed to timing issues with Medicaid payments, but management reassured that collection efforts remain strong.

The competitive landscape for Roto-Rooter appears to be stabilizing, with management noting a reduction in competitive pressures for paid leads, which could enhance future margins. Overall, Chemed Corporation demonstrated resilience in its operations, with strategic initiatives in place to address challenges while maintaining a positive outlook for the upcoming quarters.